|
Experimental model | Phytochemical class | Dose | Treatment | Molecular pathway | Cardiovascular effect | References |
|
Obesity, male rats | Quercetin | 2 mg/kg/day 10 weeks | 10 weeks | ↓ TNF-α, ↓ adiponectin | ↓ SBP | Rivera L. et al. 2008 [112] |
Hypertension, male rats | Quercetin | 10 mg/kg | 5 weeks | ↓ MDA | ↓ SBP, improves endothelial function | Duarte J. et al. 2001 [113] |
Hypertension, male rats | Quercetin | 11 mg/kg | 13 weeks | ↑ eNOS activity, ↓ NADPH generation, ↓ p47 | ↓ SBP, improves Endothelial Function | Sanchez M. et al. 2006 [114] |
Pressure overload, male rats | Quercetin | 5-10 mg/kg day | 3 weeks | ↓ MDA, ↓ ERK1/2,↓ p38, | ↓ HW/BW | Han JJ.et al. 2009 [115] |
ISO induced cardiac fibrosis, male rats | Quercetin /rutin | 25-50 mg/kg day | | ↑ SOD, ↓ angiotensin II, ↓ TGFβ1 | ↓ HW/BW | Li M. et al. 2013 [116] |
Metabolic syndrome, male rats | Quercetin | 0.8 mg/kg | 8 weeks | ↑ Nrf2, ↓ NF-κB | ↓ SBP, ↑ LVEF,↑ E/A ratio | Panchal SK. et al. 2012 [117] |
Dyslipidemia, male rats | Quercetin /ezetimibe | 0.5% w/w | 4 weeks | ↓ GSH/GSSG ratio, ↑ Nrf2 | ↑ E/A ratio | Castillo LR. et al. 2018 [118] |
Doxorubicin and I/R, male rats | Quercetin | 15 mg/kg/day | 6 weeks | ↑ MMP-2,↑ pAkt | ↓ apoptosis, improves LV relaxation | Bartekova M. et al. 2015 [119] |
I/R injury, male rats | Quercetin | 50 mg/kg/day | 5 days | ↓ HMGB1/TLR/NF-κB activity | ↑ myocardial contractility, ↑ coronary flow,↓ infarct size | Dong LY. et al. 2018 [120] |
I/R injury, male mice | Quercetin | 250 mg/kg/day | 10 days | ↑ PPAR-γ activation, ↓NF-κB pathway | ↑ LVEF, ↑ FS | Liu X. et al. 2016 [121] |
I/R injury, male rats | Resveratrol | 100 μmol/l | Before reperfusion | ↑ SOD,↓MDA,↑ Nrf2 | ↑ LVEF, improves LV relaxation, ↓ infarct size | Cheng L. et al. 2015 [131] |
I/R injury, male rats | Resveratrol | 100 μmol/l | Before reperfusion | ↓ TNF-α, ↓MPO, ↓NF-κB, ↓ TLR4 | ↓ infarct size, ↓ myocardial apoptosis | Li J. et al. 2014 [132] |
Iron-induced cardiomyopathy, male mice | Resveratrol | 320 mg/kg day | 14 weeks | Sirt1 upregulation, FOX1 downregulation, ↑ SERCA2a | ↑ E/A ratio, improves LV relaxation | Das SK. et al. 2015 [134] |
Doxorubicin-induced cardiomyopathy, male mice | Resveratrol | 15 mg/kg/day | 3 weeks | Sirt1 upregulation, ↓ p53 acetylation | ↓ myocardial apoptosis, improves LV relaxation and contractility | Zhang C. et al. 2011 [135] |
Pressure overload model, male mice | Resveratrol | 10mg/kg/day | 4 weeks | ↑SOD ↓ HIF-1α | ↓HW/BW, ↑ LVEF,↑ FS, ↓ cardiac fibrosis | Gupta PK.et al. 2014 [136] |
I/R injury, male rats | Curcumin | 150 mg/kg | 6 weeks | ↓ MDA, ↓ TGFβ/Smad pathway | ↓ cardiac fibrosis, ↑ LVEF, FS, SV | Wang NP. et al. 2012 [139] |
I/R injury, male rats | Curcumin | 300 mg/kg | 1 week | ↓ TLR2 | ↑ myocardial contractility | Kim YS. et al. 2012 [140] |
I/R injury, male rats | Curcumin | 0.25, 0.5, 1 μM | Before reperfusion | Sirt1 upregulation, ↑ SOD, ↓ MDA | ↓ infarct size, improves LV contractility | Duan W. et al. 2012 [141] |
Angiotensin II-induced cardiac fibrosis, male rats | Curcumin | 150 mg/kg | 2-4 weeks | ↓ TGFβ/Smad pathway | ↓ SBP, ↓ cardiac fibrosis | Pang XF. et al. 2015 [142] |
Surgical-induced myocardial infarction, male and female rats | Curcumin | 150 mg/kg | 4 weeks | ↓ NF-κB, ↑ PPAR-γ | ↓ cardiac fibrosis, ↓ cardiac apoptosis | Lv FH et al. 2016 [143] |
Surgical-induced MI, male rats | Curcumin | 50 mg/kg/day | 7 weeks | ↓ p300 HAT activity | ↑ FS | Morimoto T. et al. 2008 [144] |
Surgical-induced myocardial infarction, male mice | Curcumin | 100 mg/kg/day | 1 week | Sirt1 upregulation | ↓ cardiac necrosis | Xiao J. et al. 2016 [145] |
ISO-induced myocardial infarction, male rats | Curcumin nanoparticles | 100, 150, 200 mg/kg/day | 15 days | ↓ TNF-α, ↓ IL-6, IL-1α, IL-1β | ↓ cardiac necrosis | Boarescu PM. et al. 2019 [148] |
|